AC Immune (NASDAQ:ACIU) is a biopharmaceutical company focused on developing precision therapies for neurodegenerative diseases. Their operations span from research and development to the commercialization of diagnostics and treatments targeting conditions like Alzheimer's disease, Parkinson's disease, and Down syndrome-related disorders. AC Immune's project portfolio includes innovative therapeutic candidates and diagnostic tools aimed at identifying and effectively treating these complex diseases. The company's objective is to advance its pipeline of first-in-class and best-in-class molecules through clinical development, leveraging its proprietary technology platforms to address the significant unmet needs in neurodegenerative care.